Understand the source comparison
Best Research Peptides for Fatty Liver Research: Compound Comparison
Before selecting peptides for hepatic steatosis research, understanding the distinct mechanisms, dosing requirements, and measurable endpoints for each compound prevents protocol design errors that waste research time and funding. BPC-157 NF-κB pathway inhibit
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting peptides for hepatic steatosis research, understanding the distinct mechanisms, dosing requirements, and measurable endpoints for each compound prevents protocol design errors that waste research time and funding.
- BPC-157
- NF-κB pathway inhibition; gut barrier stabilisation reducing hepatic inflammation
- 200–500 mcg/day subcutaneous (rodent models)
- 4–6 weeks with daily administration
- Addresses gut-liver axis. The upstream inflammatory driver most compounds ignore
- Best choice for studies examining inflammation-driven steatosis progression to NASH
- AOD-9604
- Selective adipocyte and hepatocyte lipolysis without GH receptor binding
- 300–500 mcg/kg twice daily subcutaneous
- 6–8 weeks with consistent twice-daily dosing
- Produces hepatic lipid reduction independent of caloric restriction or systemic metabolic changes
- Ideal for isolating lipolytic effects without confounding growth hormone or insulin variables
- MOTS-c
- AMPK activation; mitochondrial biogenesis; enhanced insulin sensitivity
- 5–15 mg/kg three times weekly intraperitoneal
- 4–8 weeks depending on baseline mitochondrial dysfunction severity
- Targets the cellular energy deficit that prevents hepatocytes from oxidising accumulated triglycerides
- Most effective for models where insulin resistance and mitochondrial dysfunction are primary drivers